%0 Journal Article
%A Heinrich, Kathrin
%A Stintzing, Sebastian
%A Weikersthal, Ludwig Fischer von
%A Decker, Thomas
%A Kiani, Alexander
%A Kaiser, Florian
%A Al-Batran, Salah-Eddin
%A Heintges, Tobias
%A Lerchenmüller, Christoph
%A Kahl, Christoph
%A Seipelt, Gernot
%A Kullmann, Frank
%A Moehler, Markus
%A Scheithauer, Werner
%A Jung, Andreas
%A Holch, Julian W
%A Held, Swantje
%A Modest, Dominik Paul
%A Heinemann, Volker
%T Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
%J European journal of cancer
%V 232
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-02670
%P 116133
%D 2026
%X Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespectively of sex. However, differences relating to safety and efficacy in the treatment of mCRC between male and female patients are of growing interest.The randomized FIRE-3 study compared first-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) plus cetuximab to FOLFIRI plus bevacizumab in patients with RAS wildtype (RAS WT) mCRC. The present analysis focusses on the impact of sex and primary tumor (PT) sidedness on outcome parameters.Of 352 patients with RAS WT tumors, 249 (71 
%K Anti-EGFR (Other)
%K Cetuximab (Other)
%K Colorectal cancer (Other)
%K Gender (Other)
%K Sex (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41319450
%R 10.1016/j.ejca.2025.116133
%U https://inrepo02.dkfz.de/record/306677